Trial Radar KI
Die klinische Studie NCT01549340 für Perenniale allergische Rhinitis, Saisonale Allergische Rhinitis ist abgeschlossen. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen.
Eine Studie entspricht den Filterkriterien
Kartenansicht
Zurück zur Suche

Retrospective Record Review of Adults and Children Advised for Allergen Immunotherapy (MK-7243-022) 8.790 Immuntherapie

Abgeschlossen
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT01549340 untersuchte Perenniale allergische Rhinitis, Saisonale Allergische Rhinitis als beobachtungsstudie und hat den Status abgeschlossen. Die Studie begann am 1. November 2011 mit 8.790 Teilnehmern. Sie wurde durchgeführt von ALK-Abelló A/S und am 1. Mai 2012 abgeschlossen. Die Daten von ClinicalTrials.gov wurden zuletzt am 3. März 2017 aktualisiert.
Kurzbeschreibung
The purpose of this study is to determine the proportion of participants that initiate allergen immunotherapy (AIT) upon the recommendation of their physician and the proportion of participants that persist with their AIT throughout the recommended course.
Offizieller Titel

Evaluation of Patient Initiation and Persistence With Advised Allergen Immunotherapy

Erkrankungen
Perenniale allergische RhinitisSaisonale Allergische Rhinitis
Publikationen
Wissenschaftliche Artikel und Forschungspapiere zu dieser klinischen Studie:
Weitere Studien-IDs
  • 7243-022
NCT-Nummer
NCT01549340
Studienbeginn (tatsächlich)
2011-11
Zuletzt aktualisiert
2017-03-03
Studienende (vorauss.)
2012-05
Geplante Rekrutierung
8.790
Studientyp
Beobachtungsstudie
Status
Abgeschlossen
Stichwörter
Rhinitis
Allergen immunotherapy
Studienarme/Interventionen
Teilnehmergruppe/StudienarmIntervention/Behandlung
Participants with Allergic Rhinitis (AR)
Patients in a private allergy practice who were diagnosed with AR, with or without asthma, and advised to consider AIT between January 2005 and June 2011 and whose medical records were retrospectively reviewed.
Nicht zutreffend
Hauptergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
Percentage of Participants Advised to Start AIT Who Elected Subcutaneous Immunotherapy (SCIT) Shots or Sublingual Immunotherapy (SLIT) Drops
The percentage of participants who were advised by their physician to start AIT and elected to initiate AIT was calculated. AIT initiation was broken down by type of AIT initiated (SCIT or SLIT).
Up to 5 years
Percentage of Participants Who Initiated SCIT or SLIT and Completed 5 Years of Treatment
The percentage of participants who initiated SCIT or SLIT and completed 5 years of treatment was calculated. Duration of SCIT or SLIT was based on dates when allergy extract prescriptions were refilled. If extract refills continued past the recommended time for therapy (e.g. 5 years from the start of therapy), the participant was deemed successful in completing the recommended course. If the extract refills stopped prior to the end of the recommended time for therapy, but the last refill occurred within 6 months of the recommended time for therapy, this participant was deemed successful in completing the recommended course.
At 5 years
Duration of Treatment With SCIT or SLIT
The mean duration in years of SCIT or SLIT treatment for all participants with AR who initiated SCIT or SLIT was calculated. Duration of SCIT or SLIT was based on dates when allergy extract prescriptions were refilled.
Up to 5 years
Reason for Discontinuation of SCIT or SLIT More Than 6 Months Before Completion of the Recommended Course
The reason for discontinuation of SCIT or SLIT treatment more than 6 months before completion of the recommended course of therapy was recorded. The percentage of participants whose records were reveiwed and who discontinued SCIT or SLIT due to different reasons was calculated.
Up to 5 years
Nebenergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
Percentage of Participants With a Co-morbidity of Asthma Who Initiated SCIT or SLIT
The percentage of participants who had AR and asthma and initiated SCIT or SLIT was calculated.
Up to 5 years
Duration of SCIT or SLIT Treatment for Participants With AR and Asthma or AR Alone
The mean duration in years of SCIT or SLIT treatment for all participants with AR and asthma and for all participants with AR only was calculated. Duration of SCIT or SLIT treatment was based on dates when allergy extract prescriptions were refilled.
Up to 5 years
Eignungskriterien

Zugelassene Altersgruppen
Kind, Erwachsene, Ältere Erwachsene
Zugelassene Geschlechter
Alle
  • Diagnosis of AR with or without allergic conjunctivitis (AC)
  • Documented provider-to-patient or parent discussion of AIT as a treatment option

  • Participants receiving AIT as an AR treatment without documented provider-to-patient or parent discussion of AIT as a treatment option
  • Participants receiving immunotherapy for insect sensitivities only
  • AIT started before 2005
ALK-Abelló A/S logoALK-Abelló A/S
Keine Kontaktdaten vorhanden